Literature DB >> 22071921

Blood component ratios in massively transfused, blunt trauma patients--a time-dependent covariate analysis.

Thomas Lustenberger1, Andreas Frischknecht, Martin Brüesch, Marius J B Keel.   

Abstract

BACKGROUND: This study evaluated critical thresholds for fresh frozen plasma (FFP) and platelet (PLT) to packed red blood cell (PRBC) ratios and determined the impact of high FFP:PRBC and PLT:PRBC ratios on outcomes in patients requiring massive transfusion (MT).
METHODS: Retrospective review of a cohort of massively transfused blunt trauma patients admitted to a Level I trauma center. MT was defined as transfusion of ≥10 units of PRBC within 24 hours of admission. Critical thresholds for FFP:PRBC and PLT:PRBC ratios associated with mortality were identified using Cox regression with time-dependent variables. Impacts of high blood component ratios on 12-hour and 24-hour survival were evaluated.
RESULTS: During the 10-year study period, a total of 229 blunt trauma patients required a MT. At 12 hours and 24 hours after admission, a FFP:PRBC ratio threshold of 1:1.5 was found to have the strongest association with mortality. At 12 hours, 58 patients (25.4%) received a low (<1:1.5) and 171 patients (74.6%) a high (≥1:1.5) FFP:PRBC ratio. Patients in the low ratio group had a significantly higher mortality compared with those in the high ratio group (51.7% vs. 9.4%; adjusted hazard ratio [95% confidence interval] = 1.18 [1.04-1.34]; adjusted p = 0.008). A similar statistically significant difference was found at 24 hours after admission. For PLTs, a PLT:PRBC ratio of 1:3 was identified as the best cut-off associated with both 12-hour and 24-hour survival. At 12 hours, 79 patients (34.5%) received a low (<1:3) and 150 patients (65.5%) a high (≥1:3) PLT:PRBC ratio. After adjusting for differences between the ratio groups, no statistically significant survival advantage associated with a high PLT:PRBC ratio was found (40.5% vs. 9.3%; adjusted hazard ratio [95% confidence interval] = 1.11 [0.99-1.26]; adjusted p = 0.082).
CONCLUSION: For massively transfused blunt trauma patients, a plasma to PRBC ratio of ≥1:1.5 was associated with improved survival at 12 hours and 24 hours after hospital admission. However, for PLTs, no statistically significant survival benefit with increasing ratio was observed. The results of this analysis highlight the need for prospective studies to evaluate the clinical significance of high blood component ratios on outcome.

Entities:  

Mesh:

Year:  2011        PMID: 22071921     DOI: 10.1097/TA.0b013e318230e89b

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  14 in total

Review 1.  Coagulopathy after severe pediatric trauma.

Authors:  Sarah C Christiaans; Amy L Duhachek-Stapelman; Robert T Russell; Steven J Lisco; Jeffrey D Kerby; Jean-François Pittet
Journal:  Shock       Date:  2014-06       Impact factor: 3.454

2.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

3.  Resuscitate early with plasma and platelets or balance blood products gradually: findings from the PROMMTT study.

Authors:  Deborah J del Junco; John B Holcomb; Erin E Fox; Karen J Brasel; Herb A Phelan; Eileen M Bulger; Martin A Schreiber; Peter Muskat; Louis H Alarcon; Mitchell J Cohen; Bryan A Cotton; Charles E Wade; John G Myers; Mohammad H Rahbar
Journal:  J Trauma Acute Care Surg       Date:  2013-07       Impact factor: 3.313

Review 4.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

5.  The survival impact of plasma to red blood cell ratio in massively transfused non-trauma patients.

Authors:  P G Teixeira; K Inaba; E Karamanos; P Rhee; I Shulman; D Skiada; K Chouliaras; D Demetriades
Journal:  Eur J Trauma Emerg Surg       Date:  2016-04-27       Impact factor: 3.693

6.  Planned re-laparotomy and the need for optimization of physiology and immunology.

Authors:  L Kobayashi; R Coimbra
Journal:  Eur J Trauma Emerg Surg       Date:  2014-03-27       Impact factor: 3.693

7.  The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition.

Authors:  Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn
Journal:  Crit Care       Date:  2016-04-12       Impact factor: 9.097

Review 8.  Early and individualized goal-directed therapy for trauma-induced coagulopathy.

Authors:  Herbert Schöchl; Marc Maegele; Cristina Solomon; Klaus Görlinger; Wolfgang Voelckel
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-02-24       Impact factor: 2.953

9.  Trauma resuscitation requiring massive transfusion: a descriptive analysis of the role of ratio and time.

Authors:  Ruben Peralta; Adarsh Vijay; Ayman El-Menyar; Rafael Consunji; Husham Abdelrahman; Ashok Parchani; Ibrahim Afifi; Ahmad Zarour; Hassan Al-Thani; Rifat Latifi
Journal:  World J Emerg Surg       Date:  2015-08-14       Impact factor: 5.469

10.  Abdominal damage control surgery and reconstruction: world society of emergency surgery position paper.

Authors:  Laura Godat; Leslie Kobayashi; Todd Costantini; Raul Coimbra
Journal:  World J Emerg Surg       Date:  2013-12-17       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.